{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:50:25Z","timestamp":1773892225873,"version":"3.50.1"},"update-to":[{"DOI":"10.1016\/j.ygyno.2024.03.020","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}}],"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007760","name":"The Ohio State University College of Medicine Office of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ygyno.2024.03.020","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T16:55:10Z","timestamp":1711731310000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer"],"prefix":"10.1016","volume":"183","author":[{"given":"Courtney J.","family":"Riedinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa I.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa K.","family":"Khadraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina J.","family":"Haight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Tubbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floor J.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.03.020_bb0005","author":"Surveillance"},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.020_bb0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2022.09.014","article-title":"The contemporary presentation and diagnosis of endometrial cancer recurrence: when, where, and how?","volume":"167","author":"Riedinger","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.ygyno.2024.03.020_bb0020","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist"},{"issue":"26","key":"10.1016\/j.ygyno.2024.03.020_bb0025","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.03.020_bb0035","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial Cancer: results from the KEYNOTE-158 study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2024.03.020_bb0040","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical Activity and Safety of the Anti\u2013Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair\u2013Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"23","key":"10.1016\/j.ygyno.2024.03.020_bb0050","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial Cancer","volume":"338","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.020_bb0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2022.02.024","article-title":"Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification","volume":"165","author":"Siegenthaler","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.020_bb0060","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2006.02.011","article-title":"Follow-up after primary therapy for endometrial cancer: a systematic review","volume":"101","author":"Fung-Kee-Fung","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"36","key":"10.1016\/j.ygyno.2024.03.020_bb0070","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1200\/JCO.2015.63.9518","article-title":"Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and gynecologic oncology group study","volume":"33","author":"Goodfellow","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ygyno.2024.03.020_bb0075","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial Cancer: an NRG oncology\/gynecologic oncology group study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.03.020_bb0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data:inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med. Decis. Mak."},{"issue":"11","key":"10.1016\/j.ygyno.2024.03.020_bb0085","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/sim.4780091106","article-title":"Quality adjusted survival analysis","volume":"9","author":"Glasziou","year":"1990","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2024.03.020_bb0095","first-page":"173","article-title":"Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid","year":"2016","journal-title":"Breast Cancer: Targets and Therapy"},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2014.11.003","article-title":"Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?","volume":"136","author":"Phippen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.020_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajem.2020.12.042","article-title":"Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study","volume":"41","author":"Bledsoe","year":"2021","journal-title":"Am. J. Emerg. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2024.03.020_bb0110","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/CCM.0000000000003919","article-title":"Patient outcomes and cost-effectiveness of a Sepsis care quality improvement program in a health system","volume":"47","author":"Afshar","year":"2019","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.ygyno.2024.03.020_bb0115","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1007\/s00520-022-06826-9","article-title":"Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare advantage patients","volume":"30","author":"Gunturu","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.020_bb0120","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1200\/OP.22.00447","article-title":"Cost-effectiveness analysis of six immunotherapy-based regimens and Sunitinib in metastatic renal cell carcinoma: a public payer perspective","volume":"19","author":"Yoo","year":"2023","journal-title":"JCO Oncology Practice"},{"issue":"6","key":"10.1016\/j.ygyno.2024.03.020_bb0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jval.2011.04.008","article-title":"Economic evaluation of Everolimus versus Sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line Sunitinib","volume":"14","author":"Casciano","year":"2011","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.ygyno.2024.03.020_bb0130","doi-asserted-by":"crossref","first-page":"A557","DOI":"10.1016\/j.jval.2014.08.1835","article-title":"Comparison of methods to estimate health state Utilities in Metastatic Breast Cancer (MBC)","volume":"17","author":"Hudgens","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.ygyno.2024.03.020_bb0135","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s10198-021-01335-8","article-title":"Health state utility values by cancer stage: a systematic literature review","volume":"22","author":"Pourrahmat","year":"2021","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12955-018-0994-8","article-title":"Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients","volume":"16","author":"Paracha","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"issue":"7","key":"10.1016\/j.ygyno.2024.03.020_bb0145","doi-asserted-by":"crossref","first-page":"A646","DOI":"10.1016\/j.jval.2014.08.2341","article-title":"Generating health state utility values from fact-ovarian data collected in a phase ii maintenance study in platinum sensitive recurrent ovarian Cancer (study 19): a comparison of mapping algorithms","volume":"17","author":"Hettle","year":"2014","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.ygyno.2024.03.020_bb0150","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2014 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0155","doi-asserted-by":"crossref","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"McDougall","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.ygyno.2024.03.020_bb0160","author":"O'Neill"},{"issue":"10","key":"10.1016\/j.ygyno.2024.03.020_bb0165","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.020_bb0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ygyno.2024.03.020_bb0175","unstructured":"Esmo. (2023, M.L.d.i.n.c.s.i.a.r.e.c.R.f.t.r.t.E.p.r.E.S.o.M."},{"issue":"423","key":"10.1016\/j.ygyno.2024.03.020_bb0180","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.020_bb0185","doi-asserted-by":"crossref","DOI":"10.1097\/AOG.0000000000004676","article-title":"The changing landscape of gynecologic Cancer mortality in the United States","volume":"139","author":"Giaquinto","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.03.020_bb0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ijgc-2022-003719","article-title":"Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?","volume":"33","author":"Marques","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"26","key":"10.1016\/j.ygyno.2024.03.020_bb0195","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2024.03.020_bb0200","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2024.03.020_bb0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2024.03.020_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267322","article-title":"Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer","volume":"14","author":"You","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","article-title":"Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes","volume":"38","author":"Smare","year":"2020","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.020_bb0225","doi-asserted-by":"crossref","first-page":"A194","DOI":"10.1016\/j.jval.2014.03.1130","article-title":"PRM74 - the inherent bias from using partitioned survival models in economic evaluation","volume":"17","author":"Coyle","year":"2014","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.020_bb0230","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.020_bb0235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2021.12.007","article-title":"Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer","volume":"164","author":"Shi","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.03.020_bb0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med. Decis. Mak."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.020_bb0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1471-0528.17338","article-title":"Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: a cost-effectiveness study","volume":"130","author":"Dioun","year":"2023","journal-title":"Bjog"},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.020_bb0250","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ygyno.2021.06.014","article-title":"Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis","volume":"162","author":"Barrington","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.020_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.944931","article-title":"Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Pharmacol."}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2024.04.024","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"record-id":"53981"},{"DOI":"10.1016\/j.ygyno.2024.04.024","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}},{"DOI":"10.1016\/j.ygyno.2024.03.020","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T13:23:29Z","timestamp":1717680209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"alternative-id":["S0090825824001768"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.020","relation":{"retraction":[{"id-type":"doi","id":"10.1016\/j.ygyno.2024.03.020","asserted-by":"object"}],"erratum":[{"id-type":"doi","id":"10.1016\/j.ygyno.2024.04.024","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}